- Home
- RNAZ vs APM Comparison
RNAZ vs APM Comparison
Compare RNAZ & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- APM
- Stock Information
- Founded
- RNAZ 2016
- APM 2010
- Country
- RNAZ United States
- APM United Kingdom
- Employees
- RNAZ N/A
- APM N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- RNAZ Health Care
- APM Health Care
- Exchange
- RNAZ Nasdaq
- APM Nasdaq
- Market Cap
- RNAZ 8.3M
- APM 9.8M
- IPO Year
- RNAZ 2021
- APM 2018
- Fundamental
- Price
- RNAZ $0.32
- APM $0.79
- Analyst Decision
- RNAZ Strong Buy
- APM
- Analyst Count
- RNAZ 1
- APM 0
- Target Price
- RNAZ $3.00
- APM N/A
- AVG Volume (30 Days)
- RNAZ 606.0K
- APM 25.7K
- Earning Date
- RNAZ 11-26-2024
- APM 12-20-2024
- Dividend Yield
- RNAZ N/A
- APM N/A
- EPS Growth
- RNAZ N/A
- APM N/A
- EPS
- RNAZ N/A
- APM N/A
- Revenue
- RNAZ N/A
- APM $431,378.00
- Revenue This Year
- RNAZ N/A
- APM $157,729.10
- Revenue Next Year
- RNAZ $100.00
- APM N/A
- P/E Ratio
- RNAZ N/A
- APM N/A
- Revenue Growth
- RNAZ N/A
- APM N/A
- 52 Week Low
- RNAZ $0.22
- APM $1.09
- 52 Week High
- RNAZ $18.68
- APM $17.49
- Technical
- Relative Strength Index (RSI)
- RNAZ 33.05
- APM 16.33
- Support Level
- RNAZ $0.31
- APM $1.21
- Resistance Level
- RNAZ $0.49
- APM $1.37
- Average True Range (ATR)
- RNAZ 0.05
- APM 0.11
- MACD
- RNAZ -0.02
- APM -0.02
- Stochastic Oscillator
- RNAZ 12.67
- APM 1.33
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.